Trending...
- California: Governor Newsom honors fallen CAL FIRE Engineer
- California: Governor Newsom announces appointments 1.2.2026
- JS Gallery Brings Global Voices to LA Art Show 2026 with "OFF SCRIPT" Exhibition
Presentation will highlight this novel vascular disruptive antioxidant agent for treating wet and dry AMD with potential synergy given concurrent therapies
RIVERSIDE, Calif. - Californer -- Citrus Therapeutics, LLC, a manufacturer of innovative therapies and an early leader in novel multi-pharmacophore agents for AMD treatment, will present on its patent-pending therapeutic agent, CTZ1™, at the OIS XII event on December 2nd in San Diego, CA. CTZ1™ is the first-of-its-kind vascular disruptive agent (VDA) for treating both wet and dry AMD and was selected for this most competitive showcase for emerging ophthalmology and retina therapeutics and devices.
Citrus Therapeutics is also considered for the 2022 Ophthalmology Innovator Award for CTZ1™.
CTZ1™ is a unique vascular disruptive agent for combating the oxidative damage encountered in macular degeneration. CTZ1™ combines an antioxidant moiety fused to an angiogenic-modulating activity structure; consequently, this multi-pharmacophore combination mitigates oxidant damage experienced in AMD. CTZ1™ - as a "vascular disruptive agent" - can stabilize and temper pathological angiogenic processes secondary to progressive AMD.
More on The Californer
CTZ1™ is currently being developed with potential as a topical (i.e., eye drop solution) and local (i.e., intravitreal) therapy.
CTZ1™ makes its debut from Citrus Therapeutics, LLC, based out of Riverside, California. Citrus Therapeutics is owned and operated by Eric Chin MD, David Almeida MD MBA PhD, and Mr. Ahmad Alkayali, inventor.
For more information about CTZ1™ and its applications email salkayali@citrustherapeutics.com
About Citrus Therapeutics
Citrus Therapeutics, LLC is a U.S. company based in Riverside, California, and was formed to develop, research, and promote innovative muti-pharmacophore therapies. To learn more about CTZ1™ as a therapeutic agent for the treatment of Age-Related Macular Degeneration, visit our website here: citrustherapeutics.com
Citrus Therapeutics is also considered for the 2022 Ophthalmology Innovator Award for CTZ1™.
CTZ1™ is a unique vascular disruptive agent for combating the oxidative damage encountered in macular degeneration. CTZ1™ combines an antioxidant moiety fused to an angiogenic-modulating activity structure; consequently, this multi-pharmacophore combination mitigates oxidant damage experienced in AMD. CTZ1™ - as a "vascular disruptive agent" - can stabilize and temper pathological angiogenic processes secondary to progressive AMD.
More on The Californer
- The Best Affordable Luxury Bracelets to Shop in 2026: Timeless Style, Everyday Elegance & Lasting Shine
- Glossa Launches Categories: AI-Powered Quality Analysis That Strengthens Requirements
- Glossa Launches AI-Powered Requirements Platform to Transform Software Implementations
- California: Governor Newsom's statement on Valero's Benicia refinery update
- California: Governor Newsom announces appointments 1.6.2026
CTZ1™ is currently being developed with potential as a topical (i.e., eye drop solution) and local (i.e., intravitreal) therapy.
CTZ1™ makes its debut from Citrus Therapeutics, LLC, based out of Riverside, California. Citrus Therapeutics is owned and operated by Eric Chin MD, David Almeida MD MBA PhD, and Mr. Ahmad Alkayali, inventor.
For more information about CTZ1™ and its applications email salkayali@citrustherapeutics.com
About Citrus Therapeutics
Citrus Therapeutics, LLC is a U.S. company based in Riverside, California, and was formed to develop, research, and promote innovative muti-pharmacophore therapies. To learn more about CTZ1™ as a therapeutic agent for the treatment of Age-Related Macular Degeneration, visit our website here: citrustherapeutics.com
Source: Citrus Therapeutics
Filed Under: Medical
0 Comments
Latest on The Californer
- At Your Service Plumbing Named a 2025 Nextdoor Neighborhood Fave
- California: On eve of LA Fire Anniversary, Governor Newsom announces housing push to keep survivors in their communities
- 113 Digital Media Announces the Visibility +PR Alignment Package
- Snell & Wilmer Attorney Gregory J. Sonnenberg Named Chair of CRF-OC's Associate Board of Directors
- California: As federal aid stalls, Governor Newsom announces proposed effort to close insurance gaps for LA fire survivors, expands mortgage relief
- Southeast Ventura County YMCA Served Over 34,000 People, Provided $439,797 In Financial Ad in 2025
- BrassTranscripts Expands AI Prompt Library to 104 Templates with Sales and Pricing Calculators
- Attention ALL MEDIA COMPANIES: You are going to LOVE the ADVERTISING REVENUES from this very special kind of VALENTINE'S DAY PROMOTION!
- Custom Home Builder Connecticut Valley Homes Wins 2025 Home of the Year from the Modular Home Builders Association
- One year after LA fires: California deploys firefighting resources and advanced technology, accelerates prevention efforts
- California: Governor Newsom statement on the passing of Congressman Doug LaMalfa
- Scoop Social Co. Partners with Air Canada to Celebrate New Direct Flights to Milan with Custom Italian Piaggio Ape Gelato Carts
- Breakout Phase for Public Company: New Partnerships, Zero Debt, and $20 Million Growth Capital Position Company for 2026 Acceleration
- Japan's Patented "Hammock'n" Smartphone Band Targets Hand Fatigue From Long Phone Use
- Reditus Group Introduces A New Empirical Model for Early-Stage B2B Growth
- CCHR: Harvard Review Exposes Institutional Corruption in Global Mental Health
- NEXO, the First AI Artist From 2045, Releases Cinematic Music Video for "STACK BAGS"
- GCAC adds InJoy as Efixii NFT Coupon Reseller
- Award Winning Comedian Returns to Diamond Mountain
- IT IS WHAT IT IS by Rodrigo Angel Jimenez-Ortega